Global healthcare major Novo Nordisk on Friday announced the launch of its semaglutide injection, Ozempic, in India, which will be priced between ₹8,800 and ₹11,175 for a four-week pack. The company is aiming at a market of about 25 million, noting that three out of four people among the 100 million in the country who suffer from Type 2 diabetes currently prefer oral medicine.

However, the company has no ‘Make in India’ plan; instead, Ozempic will be imported from Denmark and sold in India, leveraging the approximately $20 billion investment made to produce it in a few global locations.

Ozempic, which is injected once a week under careful medical supervision, is said to help control diabetes and help Type 2 patients reduce weight by 7-10 per cent, according to AG Unnikrishnan, Chief Endo

See Full Page